TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

TENAYA and LUCERNE Investigators

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)914-926
Number of pages13
JournalOphthalmology
Volume131
Issue number8
DOIs
StatePublished - Aug 2024

ASJC Scopus Subject Areas

  • Ophthalmology

Keywords

  • Angiopoietin-2
  • Faricimab
  • Neovascular age-related macular degeneration
  • Vascular endothelial growth factor A
  • Vascular stability

Cite this